Prior to last Thursday's transaction, YA II CD had held a 4.0% interest in ValiRx.
Shares were down 2.7% on Monday at
Mon, 19th Mar 2018 12:46
Prior to last Thursday's transaction, YA II CD had held a 4.0% interest in ValiRx.
Shares were down 2.7% on Monday at
(ShareCast News) - Lifesciences company ValiRx reported on a "significant year" on Thursday, talking up its capital restructure and technical advancements in the 2015 calendar year. The AIM-traded firm, which focuses on cancer therapeutics and diagnostics for personalised medicine, said its Phase I/
Read more(ShareCast News) - ValiRx was pressing ahead with the trial process for its VAL201 trial treatment on Tuesday, following positive results from the most recent tranche of test patients. The AIM-traded life science company, with a focus on cancer diagnostics and therapeutics for personalised medicine,
Read more